Navigation Links
Biomerix Awarded Two Device Licenses by Health Canada
Date:4/19/2011

FREMONT, Calif., April 19, 2011 /PRNewswire/ -- Biomerix Corporation announced today it has received two Class III Medical Device Licenses by Health Canada for its REVIVE and ASSURE Hernia Repair Meshes.

REVIVE and ASSURE surgical meshes feature the Biomerix Biomaterial, a proprietary, biointegrative, synthetic tissue scaffold. The Biomerix Biomaterial is designed to play a role similar to the body's extracellular matrix, a biological structure that supports tissue repair and regeneration.  The three-dimensional, open-cell, and interconnected structure allows cells to migrate and proliferate to create new tissue. These meshes combine the strength of a synthetic material with the properties of a biologic, each offering its own set of distinctive benefits.

REVIVE is constructed with the Biomerix Biomaterial on both sides to maximize tissue ingrowth, a critical element in the repair of inguinal hernias. ASSURE is created for the repair of ventral hernias, with one side composed of the Biomerix Biomaterial to promote tissue ingrowth and the opposite side consisting of a resorbable protective film designed to minimize tissue attachment to the device in case of direct contact with the viscera.

"These regulatory approvals represent another step forward as Biomerix broadens its global reach with REVIVE and ASSURE. Both products will be distributed in Canada by Medline Industries pursuant to our exclusive distribution agreement," stated Kenneth G. Hayes, President and CEO of Biomerix Corporation.

About Biomerix

Biomerix Corporation develops and manufactures novel and proprietary materials to meet the needs of the medical, industrial, and consumer markets. Founded in 2001, Biomerix began developing a new class of polymeric material designed to support the tissue healing process. By 2004, the Company achieved a significant breakthrough and created the proprietary Biomerix Biomaterial™, a revolutionary biointegrative synthetic tissue scaffold. The Biomerix Biomaterial is a non-resorbable, cross linked, reticulated, polycarbonate polyurethane-urea consisting of an open-cell, three-dimensional, interconnected macroporous structure. This unique scaffold translates into an ability to support predictable, organized fibrovascular tissue ingrowth. The Biomerix Biomaterial is designed to play a role similar to the body's extracellular matrix (ECM), through the main phases of inflammation, proliferation, and remodeling.

For more information please call 888.308.3620 or visit www.biomerix.com.


'/>"/>
SOURCE Biomerix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biomerix Granted CE Mark for its REVIVE™ Soft Tissue Repair Mesh
2. Biomerix Ventral Hernia Repair Mesh Receives FDA 510(k) Clearance
3. OmniComm Systems Awarded 4 Clinical Trials from U.S. Biotechnology Company
4. Winner Medical CEO Awarded and Appointed Position by CNITA
5. Yuma Therapeutics Awarded a Research Grant by the Alzheimers Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimers Disease
6. Bellicum Pharmaceuticals Awarded $5.7 Million by the Cancer Prevention and Research Institute of Texas
7. $2 Million Awarded to Duke University Prevention Epicenter to Study Reduction of Healthcare-Associated Infections Using Tru-D, Total Room Ultraviolet Disinfection
8. NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease
9. NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002
10. MV Sales and Leasing Awarded HGACBuy National Contract
11. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Novavax, Inc., (Nasdaq: NVAX ) today announced that ... its RSV F protein recombinant nanoparticle vaccine candidate (RSV F ... in the journal Vaccine (the data ... conferences). The Company previously announced top line results ... RSV F Vaccine with the goal of protecting infants from ...
(Date:6/3/2017)...  Eli Lilly and Company (NYSE: ... Phase 3 MONARCH 2 study showed that abemaciclib, ... combination with fulvestrant, significantly improved progression-free survival (PFS) ... with hormone-receptor-positive (HR+), human epidermal growth factor receptor ... or progressed after endocrine therapy (median PFS, 16.4 ...
(Date:5/30/2017)... May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... Global Healthcare Conference on Tuesday, June 13, 2017, in ... , Hill-Rom,s president and chief executive officer, is scheduled to ... audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . A ... the live event through September 13, 2017. ...
Breaking Medicine Technology:
(Date:6/20/2017)... MA (PRWEB) , ... June 20, 2017 , ... Kenneth ... International AIDS Society (JIAS). , Dr. Mayer, who joined the JIAS Editorial Board ... is the founding Medical Research Director of Fenway Health and Co-Chair of ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Leading dental clinicians, ... imaging technology with the VATECH PaX-i and Anatomage systems. With advanced digital images and ... they can place dental implants precisely and restore oral health for those who are ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... Clinical Innovation Catalyst program focused on finding product improvements that could reduce ... in their throats when they need help breathing or to provide medication. Sometimes, ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... staffing agency, recently became re-accredited by the Joint Commission, which accredits ... Commission accreditation and certification is recognized nationwide as a symbol of quality that ...
(Date:6/20/2017)... ... 20, 2017 , ... The law firm of Momkus McCluskey Roberts LLC ... of the DuPage County Bar Association’s Board of Directors. Cassioppi officially took on the ... Drake in Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was also ...
Breaking Medicine News(10 mins):